EICHORPublic-registry site landscape for NCT04311515, “To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia”, a Alzheimer Disease study sponsored by Samus Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04311515 (registry record) |
| Study title | To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia |
| Official title | A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia |
| Sponsor | Samus Therapeutics, Inc. |
| Condition(s) | Alzheimer Disease |
| Phase | PHASE2 |
| Listed sites | 10 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04311515.
Eichor generates a preliminary site-risk snapshot for NCT04311515 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Alzheimer Disease trials
← Eichor home · All tracked trials · Alzheimer Disease studies · Weekly briefs
